Literature DB >> 25659907

Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.

Baoyu Zhao1, Sonu Gandhi2, Cai Yuan1, Zhipu Luo1, Rui Li3, Henrik Gårdsvoll4, Valentina de Lorenzi2, Nicolai Sidenius2, Mingdong Huang5, Michael Ploug6.   

Abstract

The urokinase-type plasminogen activator receptor (uPAR) is a multidomain glycolipid-anchored membrane protein, which facilitates extracellular matrix remodeling by focalizing plasminogen activation to cell surfaces via its high-affinity interaction with uPA. The modular assembly of its three LU (Ly6/uPAR-like) domains is inherently flexible and binding of uPA drives uPAR into its closed conformation, which presents the higher-affinity state for vitronectin thus providing an allosteric regulatory mechanism. Using a new class of epitope-mapped anti-uPAR monoclonal antibodies (mAbs), we now demonstrate that the reciprocal stabilization is indeed also possible. By surface plasmon resonance studies, we show that these mAbs and vitronectin have overlapping binding sites on uPAR and that they share Arg91 as hotspot residue in their binding interfaces. The crystal structure solved for one of these uPAR·mAb complexes at 3.0Å clearly shows that this mAb preselects the closed uPAR conformation with an empty but correctly assembled large hydrophobic binding cavity for uPA. Accordingly, these mAbs inhibit the uPAR-dependent lamellipodia formation and migration on vitronectin-coated matrices irrespective of the conformational status of uPAR and its occupancy with uPA. This is the first study to the best of our knowledge, showing that the dynamic assembly of the three LU domains in uPARwt can be driven toward the closed form by an external ligand, which is not engaging the hydrophobic uPA binding cavity. As this binding interface is also exploited by the somatomedin B domain of vitronectin, therefore, this relationship should be taken into consideration when exploring uPAR-dependent cell adhesion and migration in vitronectin-rich environments.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD87; LU domains; allosteric regulation; surface plasmon resonance; urokinase

Mesh:

Substances:

Year:  2015        PMID: 25659907     DOI: 10.1016/j.jmb.2015.01.022

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  14 in total

1.  Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?

Authors:  Julie M Leth; Haydyn D T Mertens; Katrine Zinck Leth-Espensen; Thomas J D Jørgensen; Michael Ploug
Journal:  J Biol Chem       Date:  2019-03-20       Impact factor: 5.157

2.  Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL.

Authors:  Xuchen Hu; Mark W Sleeman; Kazuya Miyashita; MacRae F Linton; Christopher M Allan; Cuiwen He; Mikael Larsson; Yiping Tu; Norma P Sandoval; Rachel S Jung; Alaleh Mapar; Tetsuo Machida; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2016-11-15       Impact factor: 5.922

3.  Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

Authors:  Valentina De Lorenzi; Gian Maria Sarra Ferraris; Jeppe B Madsen; Michela Lupia; Peter A Andreasen; Nicolai Sidenius
Journal:  EMBO Rep       Date:  2016-05-17       Impact factor: 8.807

4.  A two-step ensemble learning for predicting protein hot spot residues from whole protein sequence.

Authors:  SiJie Yao; ChunHou Zheng; Bing Wang; Peng Chen
Journal:  Amino Acids       Date:  2022-01-30       Impact factor: 3.520

5.  Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction.

Authors:  Khuchtumur Bum-Erdene; Degang Liu; David Xu; Mona K Ghozayel; Samy O Meroueh
Journal:  ACS Med Chem Lett       Date:  2020-12-10       Impact factor: 4.345

6.  The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain.

Authors:  Simon Mysling; Kristian Kølby Kristensen; Mikael Larsson; Anne P Beigneux; Henrik Gårdsvoll; Loren G Fong; André Bensadouen; Thomas Jd Jørgensen; Stephen G Young; Michael Ploug
Journal:  Elife       Date:  2016-01-03       Impact factor: 8.140

Review 7.  Evolution and Medical Significance of LU Domain-Containing Proteins.

Authors:  Julie Maja Leth; Katrine Zinck Leth-Espensen; Kristian Kølby Kristensen; Anni Kumari; Anne-Marie Lund Winther; Stephen G Young; Michael Ploug
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

Review 8.  Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.

Authors:  V M Baart; R D Houvast; L F de Geus-Oei; P H A Quax; P J K Kuppen; A L Vahrmeijer; C F M Sier
Journal:  EJNMMI Res       Date:  2020-07-28       Impact factor: 3.138

9.  Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.

Authors:  Baoyu Zhao; Sonu Gandhi; Cai Yuan; Zhipu Luo; Rui Li; Henrik Gårdsvoll; Valentina de Lorenzi; Nicolai Sidenius; Mingdong Huang; Michael Ploug
Journal:  Data Brief       Date:  2015-09-04

10.  Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain.

Authors:  Yunbin Jiang; Lin Lin; Shanli Chen; Longguang Jiang; Mette C Kriegbaum; Henrik Gårdsvoll; Line V Hansen; Jinyu Li; Michael Ploug; Cai Yuan; Mingdong Huang
Journal:  Int J Biol Sci       Date:  2020-01-30       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.